抗体

GRIA2

030274

100微升

502美元

单克隆

小鼠

未共轭

13B352

人类, 大鼠

GRIA2

小鼠

单克隆抗体

抗体

100微升

502美元

13B352

IgG1

Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. This gene product belongs to a family of glutamate receptors that are sensitive to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), and function as ligand-activated cation channels. These channels are assembled from 4 related subunits, Gria1-4. The subunit encoded by this gene (Gria2) is subject to RNA editing (Q:R and R:G), which is thought to render the channels impermeable to Ca(2+), and to affect the kinetic aspects of these channels in rat brain. Alternative splicing, resulting in transcript variants encoding different isoforms (flip and flop), has been noted for this gene. Applications: Western Blot: 1:500-1:2000 Flow Cytometry: 1:200-1:400 ELISA: 1:10000 Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Hu

GluA2; GluR2; gluR-B; GluR-K2

纯化重组片段对应于人GRIA2(AA: 652-807)在大肠杆菌中表达

人类

纯化

Purified antibody in PBS with 0.05% sodium azide and 0.5% protein stabilizer.

~1毫克/毫升

Product Type: Mab Isotype: IgG1 Clone No: 13B352 Host: mouse Source: human Concentration: ~1mg/ml Form: Purified antibody in PBS with 0.05% sodium azide and 0.5% protein stabilizer. Purity: Purified Immunogen: Purified recombinant fragment of human GRIA2 (AA: 652-807) expressed in E. coli. Specificity: Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

E FC免疫印迹

-20°C

1.Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Feb;24(4):173-6. 2.Neurosci Lett. 2011 Jun 15;497(1):42-5.